Super Trillion Common Light Chain Antibody Discovery Platform Launched

As One Of The Nine Trillion Antibody Discovery Platforms Of Sanyou, The Platform Features A Library Capacity Of Up To 1.12E+12 Cfu. For A Single Target, The Platform Can Generate Hundreds Of Lead Antibodies With Diverse Sequences, Which Can Be Further Designed Into Bispecific Antibodies With Good Drug Developability, Providing A Feasible Solution For Obtaining Bispecific Antibodies With Structures Similar To The Natural Monoclonal Antibodies.Bispecific Antibodies Are At The Forefront Of Antibody R&D Field. Compared With Monoclonal Antibodies, Bispecific Antibodies Possess One Additional Antigen Binding Arm, Which Brings Stronger Specificity And Better Targeting. As Of March Of 2023, 436 Bispecific Antibody Drug Candidates Have Advanced To Clinical Trials Worldwide, And 10 Bispecific Antibody Drugs Had Been Approved For Marketing, With Sales Of More Than 5 Billion Usd.The Antibody Library Of The Platform Was Established In A Rigorous Way. To Be Specific, 2 Common Light Chains Were Selected Through Alignment And Screening Of 1800+ Light Chain Sequences, Validation Of 25 Proof-Of-Concept Libraries, And Antibody Characterization And Analysis Of 12 Light Chains. The Bispecific Antibodies Generated By This Platform Exhibit Good Drug Developability, And The Heavy Chains Possess Natural Antibody Properties And High Diversity. The Platform Employs The Knob-Into-Hole Technology To Ensure The Correct Pairing In The Process Of Bispecific Antibody Formation And Eliminate The Mismatch. These Common Light Chain Antibodies Are Suitable For Multiple Application Scenarios, Such As Bispecific Antibody Development, Dual-Targeting Or Bi-Paratopic Adc, And Therapeutic Or Detection Antibodies.Following The Customer-Oriented Concept, The Platform Provides Two Types Of Services, I.E., Library Screening And Library Integration, Making It Not Only Suitable For The R&D Service Of Individual Projects, But Also For Customers

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!